ABT.SW stock opened sharply lower intraday on 02 Mar 2026, trading at CHF88.00 after a 12.00% drop from a previous close of CHF100.00 on the SIX Swiss exchange. The slide makes Abbott Laboratories one of the top losers in the Healthcare sector today in Switzerland. Key fundamentals still show an EPS of CHF2.89 and a PE of 30.45, while volume is light at 10.00 shares so far. Meyka AI, an AI-powered market analysis platform, flags oversold technicals and mixed valuation signals as catalysts to watch.

ABT.SW stock: intraday price action and drivers

Intraday the stock moved to CHF88.00 with a one-day decline of 12.00%. One clear driver is a sharp re-rating versus the 50-day average of CHF95.35 and the 200-day average of CHF101.01. The year high is CHF106.00 and the year low is CHF85.00, so today’s price tests recent support zones. Low traded volume at 10.00 shares suggests price moved on limited liquidity rather than broad selling.

ABT.SW stock: valuation and fundamentals

Abbott Laboratories on SIX shows a PE ratio of 30.45 and EPS of CHF2.89, reflecting premium valuation for a Medical – Devices peer. Price-to-sales is 4.49 and price-to-book is 3.84. Balance-sheet metrics include debt-to-equity of 0.29 and a current ratio of 1.58, indicating moderate leverage and adequate short-term liquidity. Dividend metrics show a dividend per share of CHF2.52 and yield near 2.20%.

ABT.SW stock: technicals, momentum and sector context

Technically ABT.SW stock is oversold with an RSI of 14.95, and MACD reading negative at -2.77 (signal -1.40). ADX at 88.92 signals a strong trending move, here to the downside. Healthcare sector peers have outperformed year-to-date, so Abbott’s -12.00% intraday move contrasts with broader sector metrics. Investors should watch short-term support near CHF85.00 and resistance at CHF95.00.

ABT.SW stock: Meyka AI grade and technical assessment

Meyka AI rates ABT.SW with a score out of 100: 74.52 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show oversold momentum and high ADX strength, supporting a tactical watch for mean reversion or deeper correction. These grades are not guaranteed and we are not financial advisors.

ABT.SW stock: risks, catalysts and near-term outlook

Key risks include valuation compression if growth slows, currency moves impacting CHF listings, and weaker demand for diagnostics or devices. Near-term catalysts are quarterly earnings (next announcement 15 Apr 2026) and any sector-wide updates on device approvals or diagnostic demand. With free cash flow yield around 3.71% and payout ratio 0.63, capital return remains a partial support for valuation.

ABT.SW stock: trading strategy and price levels to watch

For intraday and short-term traders, consider support at CHF85.00 and a near resistance target CHF95.00. A conservative 12-month price target from Meyka forecasts sits near CHF100.11. Use stop-losses under CHF84.00 on size-limited trades and watch liquidity; current intraday volume is only 10.00 shares, raising execution risk. See the company page for continual updates: ABT.SW on Meyka.

Final Thoughts

ABT.SW stock is the day’s top loser on SIX after a 12.00% intraday fall to CHF88.00, testing its recent low near CHF85.00. Valuation remains above many peers with a PE of 30.45, P/S of 4.49, and P/B of 3.84, while the balance sheet shows low leverage with debt-to-equity 0.29. Meyka AI’s forecast model projects a 12-month target near CHF100.11, implying a potential 12.86% upside from CHF88.00, while shorter-horizon model points are mixed. Specifically, Meyka AI’s forecast model projects quarterly CHF129.29 (+46.93% implied) and monthly CHF50.62 (-42.50% implied). Forecasts are model-based projections and not guarantees. Given oversold technicals (RSI 14.95) and relatively light volume (10.00 shares), the immediate trade is high risk; traders should weigh support at CHF85.00 and resistance at CHF95.00 and monitor upcoming earnings on 15 Apr 2026 for a clearer catalyst.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.